Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant

(1) Introduction: Invasive fungal infections (IFIs) are a major cause of morbidity and mortality among immunocompromised patients with hematologic malignancies (HM) and stem cell transplants (SCT). Isavuconazole was approved by FDA as a primary therapy for Invasive Aspergillosis (IA) and Mucormycosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dagher, Hiba, Hachem, Ray, Chaftari, Anne-Marie, Jiang, Ying, Ali, Shahnoor, Deeba, Rita, Shah, Shivan, Raad, Issam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779319/
https://www.ncbi.nlm.nih.gov/pubmed/35050014
http://dx.doi.org/10.3390/jof8010074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779319/
https://www.ncbi.nlm.nih.gov/pubmed/35050014
http://dx.doi.org/10.3390/jof8010074

Ejemplares similares